CD19 and neoplasm: When the CAR-T cell product from CR patients was compared to those from NR patients in an immunodeficient murine xenograft model (NSG mice engrafted with the CD19 positive NALM-cell line), CR patient derived CAR-T cells expanded more and caused superior tumour regression.